Center-Authored Papers

Filters: Author is Gao, Hongmei  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Perez LG, Martinez DR, Decamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H et al..  2017.  V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.. PloS one. 12(7):e0180720. Abstract
T
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X et al..  2012.  The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120.. AIDS research and human retroviruses. 28(11):1444-57. Abstract
P
Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L et al..  2013.  Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial.. PloS one. 8(9):e75665. Abstract
Hraber P, Rademeyer C, Williamson C, Seaman MS, Gottardo R, Tang H, Greene K, Gao H, Labranche C, Mascola JR et al..  2017.  Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.. Journal of virology. Abstract
M
Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E et al..  2012.  Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials.. The Journal of infectious diseases. 206(3):431-41. Abstract
I
Kong R, Louder MK, Wagh K, Bailer RT, DeCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C et al..  2015.  Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.. Journal of virology. 89(5):2659-71. Abstract
G
DeCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H et al..  2014.  Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies.. Journal of virology. 88(5):2489-507. Abstract
F
Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR et al..  2016.  Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.. PLoS pathogens. 12(7):e1005742. Abstract
D
Huang Y, Ferrari G, Alter G, Forthal DN, Kappes JC, Lewis GK, Love CJ, Borate B, Harris L, Greene K et al..  2016.  Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.. Journal of immunology (Baltimore, Md. : 1950). 197(12):4603-4612. Abstract
Todd CA, Greene KM, Yu X, Ozaki DA, Gao H, Huang Y, Wang M, Li G, Brown R, Wood B et al..  2012.  Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.. Journal of immunological methods. 375(1-2):57-67. Abstract